Pharnext S.A.

Plus: Erasca promotes Morris, Lovejoy and updates from Poseida, Mithra, Tune, Cellarity and more

Plus: BioTheryX, BioCryst, Redx, Tango, Epizyme and more

Citing the totality of available data and an evolving treatment landscape for acute myelogenous leukemia, Johnson & Johnson (NYSE:JNJ) returned rights to anti-CD70 antibody cusatuzumab, for which

Mark Shearman will join Editas Medicine Inc. (NASDAQ:EDIT) in June as EVP and CSO. Shearman currently serves as CSO of Applied Genetic Technologies Corp. (NASDAQ:AGTC). Kyowa Kirin Co. Ltd.

Truffle Capital plans to deploy €250M fund to scour the U.S., Europe for IP to build biotechs, medtechs